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Chemical Mediators and the
Resolution of Airway Inflammation
Troy Carlo1 and Bruce D Levy1
ABSTRACT
Asthma pathobiology is remarkable for chronic airway inflammation that fails to spontaneously resolve. No
curative therapy is currently available. A growing body of evidence indicates that, in health, inflammation reso-
lution is an active process orchestrated by specific chemical mediators that are elaborated to restore tissue ho-
meostasis. Activated cell membranes release polyunsaturated fatty acids from phospholipids for enzymatic
conversion to biologically active mediators with profound regulatory effects on innate and adaptive immunity.
Some of these mediators carry anti-inflammatory and pro-resolving actions that are transduced in a cell-type
specific manner via specific recognition sites that initiate regulatory intracellular signals, such as presqualene
diphosphate remodeling, to limit pro-phlogistic cell activation. Some of these counter-regulatory lipid mediators
have been identified in the airway during asthma and defects in their production are associated with disease
severity. In this review, we describe the biosynthesis and bioactions of pro-resolving chemical mediators and
provide examples of select mediators and their structural analogs with particular relevance to asthma.
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INTRODUCTION
“Asthma is a chronic relapsing inflammatory disorder
characterized by hyperreactive airways, leading to epi-
sodic, reversible bronchoconstriction, owing to increased
responsiveness of the tracheobronchial tree to various
stimuli.” 1
In many parts of the world, asthma morbidity and
mortality is high and increasing.2 An estimated 300
million people are currently suffering from the dis-
ease. In the United States, approximately 10% of indi-
viduals will have asthma in their lifetime. Japan has
one of the highest prevalences in Asia with 6.7% of
the population being asthmatic. The number of
asthma patients treated at Japanese medical facilities
has increased 330 fold in the last 30 years. Most pa-
tients with persistent asthma have mild to moderate
disease. Their symptoms are controlled to a great ex-
tent by anti-inflammatory therapies, in particular in-
haled corticosteroids. Long-term use of corticoster-
oids is associated with side effects that highlight the
need for additional therapeutics. A minority of pa-
tients is classified as having severe asthma. While
this group comprises only 5 to 10% of all asthmatics,
they account for the majority of hospitalizations,
emergency room visits, and mortality associated with
asthma.3 Patients with severe asthma have symptoms
that are refractory to current therapy and that consti-
tute an important unmet need in asthma manage-
ment.
Asthma is characterized by chronic airway inflam-
mation punctuated by exacerbations with acute in-
flammatory responses. In most instances the airway
inflammation does not resolve completely. To restore
airway homeostasis, avoidance of allergen or provoca-
tive stimulus can lead to a passive decrease in pro-
inflammatory effectors. However, a growing body of
evidence supports a signaling network that actively
promotes the resolution of inflammation in tissue ca-
tabasis. Several classes of natural anti-inflammatory
chemical mediators have been identified that are pro-
duced at sites of inflammation. Here, we review re-
cent progress in the biosynthesis and bioactions of
pro-resolving chemical mediators and provide exam-
ples of select mediators with particular relevance to
asthma.
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LIPOXINS
Lipoxins (LXs) are lipoxygenase (LO) interaction
products of arachidonic acid metabolism that were
first discovered in 1984.4 LXs were the first com-
pounds identified to carry properties of pro-resolving
mediators.5 These eicosanoids are structurally and
functionally distinct from pro-inflammatory prostag-
landins and leukotrienes.5 LXs are produced at sites
of inflammation via cell-cell interactions. Activated
epithelial cell 15-LO can convert arachidonic acid
to 15(S)-hydroperoxyeicosatetraenoic acid [15 (S)-
HpETE] that can be further transformed by neutro-
phil (PMN) and eosinophil (EOS) 5-LO to produce
LX.5 Of interest, 15 (R)-HETE can be generated from
arachidonic acid by either aspirin acetylated cy-
clooxygenase (COX)-2 or cytochrome p450 activity.
15(R)-HETE can also be further modified by 5-LO,
leading to the generation of 15-epimer-LXs (15-epi-
LXs).6
LXs and 15-epi-LXs signal via interactions with spe-
cific receptors. The LXA4 receptor is termed ALX and
binds LXA4 with high affinity (Kd 0.7 nM).7 ALX is a
seven transmembrane spanning G protein coupled
protein that is expressed on human airway epithelial
cells, PMNs, monocytes, enterocytes and synovial fi-
broblasts.7-11 Airway inflammation or injury increases
ALX expression on both proximal airway and distal al-
veolar cells.8,12 In addition to binding to LXA4 and 15-
epi-LXA4, ALX can also recognize annexin 1, although
with lower affinity than LXA4.13,14 Annexin 1 is an
anti-inflammatory peptide that is induced by gluco-
cortocoids,15 a frequent asthma therapy. LXs can also
act as a receptor level antagonist to a subclass of
LTD4 receptors (CysLT1 receptors).16 LXs also bind
to the aryl hydrocarbon receptor, a ligand activated
transcription factor.17 Intracellular sites for LX recog-
nition and transport have also been identified.18 Thus,
LXs can serve as agonists at cognate receptors to in-
itiate counter-regulatory signals and, in some cases,
share recognition sties with pro-inflammatory media-
tors to serve as antagonists for pro-phlogistic signals.
LXs are produced in many human inflammatory
lung diseases, including asthma. Of interest, severe
asthma is characterized by diminished LX production
with confirmatory data now available from three dif-
ferent continents in ethnically diverse popula-
tions.19-21 In addition, the capacity to generate LXA4
in whole blood correlates with lung function (FEV1%
predicted).19-21 LXs are produced at sites of airway in-
flammation and have many relevant cell-type specific
effects on functional responses in asthma (see Table
1). For example, LXs are potent stop signals for PMN
chemotaxis, trans-endothelial and trans-epithelial mi-
gration, production of reactive oxygen species, and
azurophilic granule release.22-25 In contrast, they pro-
mote monocyte locomotion26 and macrophage medi-
ated clearance of apoptotic PMN and microbial prod-
ucts by phagocytosis.27 Distinct from immunosup-
pressive agents, LXs are host protective in experi-
mental model systems. LXs and their stable analogs
prevent PMN mediated tissue injury (reactive oxygen
species), enhance bronchial epithelial cell prolifera-
tion in response to injury, and block the release of
pro-inflammatory cytokines from epithelial cells.8 In
addition, LXs increase epithelial cell anti-infective ac-
tivity.28 Taken together, these data define LXs as ho-
meostatic mediators that are anti-inflammatory and
pro-resolving to promote tissue catabasis.
PRESQUALENE DIPHOSPHATE
In many individuals with severe asthma, PMN accu-
mulation and activation in the airway characterizes
their pathobiology. During a screen for counter-
regulatory lipid mediators, presqualene diphosphate
(PSDP) was identified as an intracellular signal in hu-
man peripheral blood PMNs.29 PSDP is present in
resting cell membranes and transiently remodels to
presqualene monophosphate (PSMP) within seconds
of receptor mediated cell activation.29,30 Addition of
biologically relevant quantities (nM) of PSDP, but not
its monophosphate form (PSMP), inhibits O2¯ pro-
duction from PMNs. Both phospholipase D (PLD)
and phosphatidylinositol 3-kinase (PI3K) activity are
important signal transduction pathways for rapid as-
sembly of the NADPH oxidase (reviewed in31,32). Of
interest, PSDP directly interacts with PMN PI3Kγ as
it deactivates and PSDP can potently block PI3Kγ ac-
tivity in vitro.33 In addition, PSDP can inhibit PLD ac-
tivity from plant, microbial and mammalian origin
(Fig. 1).24,34 Taken together, these data depict an in-
tracellular signaling role for PSDP in the regulation of
cell activation.
Consistent with an anti-inflammatory role, the intra-
cellular levels of PSDP in human PMN rapidly, within
seconds, decrease upon PMN exposure to pro-
inflammatory agonists and these decrements are ac-
companied by a reciprocal increase in PSMP. 15-epi
LXA4 blocks leukotriene B4 mediated PSDP remodel-
ing, PLD activation and O2¯ generation (Fig. 1).23
PSMP, which differs from PSDP by only a phosphate,
does not inhibit PI3K, PLD or O2¯ production by
PMN. Thus, the timing and reciprocal changes in
amounts of PSDP and PSMP appear to regulate cell
activation and suggest the presence of a pivotal phos-
phatase that converts PSDP to PSMP upon cellular
stimulation.
A candidate PSDP phosphatase was recently identi-
fied and named polyisoprenyl diphosphate phos-
phatase 1 (PDP1) (see Fig. 1).35 By sequence analy-
sis, PDP1, formerly referred to as CSS2α and
PPAPDC2 (GeneID 403313), was determined to be a
member of the lipid phosphate phosphatasephos-
photransferase (LPT) family of integral membrane
proteins (see Fig. 2). LPT proteins are characterized
by a core consisting of six transmembrane domains
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Table 1 Cel type-specific counter-regulatory mechanisms for chemical mediators of resolution
Ref (s)Action/ResponseMediatorCel Type
64, 65Blocks migration and chemotaxisLXA4EOS
 66Blocks IL-12 ProductionLXA4Dendritic cel
 67Blocks IL-12 ProductionRvE1
 42Inhibits migration
22Inhibits chemotaxisLXA4PMN
49, 50Stops trans-endothelial and trans-epithelial migration
23Blocks superoxide anion generation
25Blocks azurophilic granule release
23Blocks LTB4 mediated PSDP remodeling
29Blocks superoxide anion generationPSDP
33Inhibits PI3Kγ activity
23Inhibits PLD activity
39Inhibits trans-endothelial and trans-epithelial migrationRvE1
68Inhibits superoxide anion generation
18, 55Stops transmigrationAspirin-triggered RvD1
27Stimulates phagocytosis of apoptotic PMNLXA4Monocyte 
Macrophage 26, 55Enhances chemotaxis and adhesion to lamin
69Blocks peroxynitrite generation
70Reduces IL-8 release from cels isolated from asthmatics
50Stimulates phagocytosis of apoptotic PMNRvE1
54Blocks LPS-induced TNF releaseRvD1
54Blocks LPS-induced TNF releasePD1
 8Basal cel proliferation after acid injuryLXA4Bronchial Epithelial 
Cels  8Blocks IL-6 and IL-8 release
with a catalytic center split between two interacting
loops external to the membrane (reviewed in Sigal YJ
et al.36). Other members of the LPT family participate
in lipid metabolism, cell migration, and apoptosis.
While several LPT proteins use multiple phospholip-
ids as substrates, PDP1 has a distinct substrate pref-
erence for polyisoprenyl diphosphates (i.e. PSDP and
farnesyl diphosphate) over phosphatidic acid.35 Sug-
gestive of a role in signal transduction, PDP1 is ac-
tively phosphorylated in response to cellular ago-
nists.37 Anti-inflammatory properties of HMG-CoA re-
ductase inhibitors (i.e., statins) in airway inflamma-
tion38 suggests immunoregulatory roles for iso-
prenoids, like PSDP, in the pathology of asthma.
RESOLVINS
Resolvins were first identified in resolving inflamma-
tory exudates and are now recognized as a class of
anti-inflammatory, pro-resolving lipid mediators de-
rived from omega-3 polyunsaturated fatty acids.39
Currently, there are two reported series of resolvins.
The D series resolvins are enzymatically derived
from docosahexaenoic acid (DHA) and the E series
arise from eicosapentaenoic acid (EPA).39,40 To gen-
erate E series resolvins (RvEs), aspirin acetylated
COX-2 from endothelial cells or cytochrome p450
converts EPA to 18R-hydroxyeicosapentaenoic acid
(18 (R)-HEPE),39 which is subsequently modified by
PMN LOs to form the bioactive RvEs.39,41 A receptor
for RvE1 has been identified as ChemR23.42
ChemR23 is expressed on monocytes, macrophages
and dendritic cells. Similar to ALX, the ChemR23 re-
ceptor binds to both lipid and peptide ligands. The
protein chemerin is a peptide ligand for ChemR23
and appears to have a role in inflammation resolution.
Chemerin is a macrophage and dendritic cell
chemoattractant found in inflammatory exudates,43
and mice deficient for the ChemR23 gene display en-
hanced levels of inflammation.44 RvE1 can also inter-
act with BLT1, and serves as a receptor level antago-
nistpartial agonist.45 BLT1 is a receptor for the pro-
inflammatory cytokine LTB4 and is expressed on
PMN, EOS, monocytes and T-cells.46 Together, an-
tagonist activity for pro-inflammatory BLT1 receptors
and agonist activity for anti-inflammatory ChemR23
receptors provide a molecular basis for the pro-
resolution effects of RvE1.
Similar to LXs and 15-epi-LXs, the D series re-
solvins can be produced in both an R and an S confor-
mation. The 17S D series resolvins are generated in
whole blood, while the 17R conformers are created
via interactions between aspirin acetylated COX-2
from endothelial cells and LO activity from PMN.46-48
RvD1 is a potent regulator of renal ischemia-
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Fig. 1 Ilustration of celular PSDP remodeling. Activation of PMNs results in the 
rapid and transient conversion of PSDP to PSMP concurent with functional re-
sponses, such as superoxide anion generation, PLD and PI3K activity. PSDP re-
modeling is mediated by polyisoprenyl diphosphate phosphatase 1 (PDP1) and 
PSDP dephosphorylation is blocked by LX signaling. PSDP and PSMP are drawn 
with Chem3D Pro. The color scheme is as folows: red-oxygen, pink-phosphorus, 
blue-hydrogen, and grey-carbon.
PDP1
PSMP
・Unknown Biological
Function
ALX
LX
PSDP
・Inhibition of O2－
・Inhibition of PLD 
and PI3K
・Interacts with 
SH2 Domains
Fig. 2 Evolutionary dendrogram based on sequence similarity among the lipid 
phosphate/phosphotransferase family members. Adapted from reference.36
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reperfusion in mice,49 but no information is presently
available in asthma.
In the setting of experimental acute inflammation,
resolvins display properties that are likely to be bene-
ficial in resolving allergic airway responses. Resolvin
E1 inhibits PMN transmigration and promotes the
phagocytosis of apoptotic PMN by macrophages39,50
(Table 1). Of note, clinical studies demonstrate an in-
crease in quality of life assessment for asthmatics
placed on diets enriched with EPA and γ-linolenic
acid (GLA).51 In addition, enteral feeding with diets
enriched in EPA, GLA, and antioxidants improves
clinical outcomes of critically ill patients with the
acute respiratory distress syndrome.52,53 Resolvins
Resolution of Airway Inflammation
Allergology International Vol 57, No4, 2008 www.jsaweb.jp 303
Table 2 Efects of chemical mediators, their mimetics and ALX signaling on the resolution of airway inflammation＊
Ref (s)
Regulation of Airway Responses
MediatorExperimental Model
MucusAHRTH2CytokinesWBC
12, 63n.d.YESYESEOS/LYLX and LXanalogs
Ovalbumin-mediated alergic 
airway inflammation
12n.d.NOYESEOS/LYCD11b-hALX trans-genic mouse
58YESYESYESEOS/LYPD1
56, 57YESYESYESEOS/LYRvE1
63n.d.YESYESEOS/LYLX and LXanalogs
Cockroach alergen-mediated 
alergic airway inflammation
 8n.d.n.d.n.d.PMNCD11b-hALX trans-genic mouse
Acid-initiated acute lung injury
33n.d.n.d.n.d.PMNPSDP mimetic
＊Regulation of airway inflammatory phenotype for select chemical mediators and their signaling receptors are indicated for leukocyte traf-
ficking (EOS-eosinophil, Ly-lymphocyte, PMN-neutrophil), bronchoalveolar lavage fluid TH2 inflammatory (TH2) cytokines, airway hypere-
sponsiveness (AHR), and airway mucus (periodic acid Schif staining).
have yet to be identified in lung disease, yet their
anti-inflammatory effects in models of peritonitis and
ischemia-reperfusion injury suggest that resolvins
would also be lung protective.47,54,55 In this area of ac-
tive research, preliminary findings have recently
linked RvE1 to control of allergic airway responses in
a murine model of asthma.56,57
PROTECTINS
Protectin D1 (PD1) is the first member of a distinct
class of DHA-derived counter-regulatory lipid media-
tors. PD1 is a 10R, 17S-docosatriene, and similar to
LXs, PD1 production is reliant of 15-LO activity.39,47
PD1 is found in human exhaled breath condensates
and, of interest, PD1 levels are significantly de-
creased in exhaled breath condensates from patients
with asthma exacerbations relative to healthy control
subjects.58 In a murine model of asthma, administra-
tion of PD1 prior to aeroallergen challenge reduced
EOS and lymphocyte recruitment, as well as the lev-
els of TH2 inflammatory cytokines. In addition, PD1
pretreatment led to decrements in airway mucus and
hyperresponsiveness to inhaled methacholine.58 The
generation of both PD1 and LXs is linked to 15-
LO,5,39,47 and severe asthma is characterized by de-
creased 15-LO expression and activity.59 Thus, severe
or uncontrolled asthma appears to represent LX and
PD1 deficient states.
THERAPEUTIC POTENTIAL
While LXs, 15-epi LXs, resolvins and protectins can
promote the resolution of inflammation, they are au-
tacoids that are rapidly inactivated. In the only human
intervention trial reported to date with LXs, admini-
stration of nebulized LXA4 (10−4M) to human subjects
with mild asthma dampened leukotriene C4 mediated
bronchoconstriction without indications of deleteri-
ous side effects.60 The use of high doses of LXA4 was
necessitated by the compound’s rapid inactivation.
Subsequently, three generations of LX mimetics have
been prepared and are effective when administered
orally, via intraperitoneal injection, or intrave-
nously.61,62 In the lung, LX mimetics inhibit both air-
way hyper-responsiveness and inflammation in two
distinct murine models of asthma12,63 and PSDP mi-
metics dampen acid initiated acute murine lung in-
jury33 (Table 2). Resolvin and PD1 analogs are cur-
rently undergoing design and testing. Mimetics of
these chemical mediators hold promise for providing
multi-pronged relief from pathologic airway re-
sponses by serving as pro-resolving agonists andor
inflammatory antagonists in stimulating a pro-
grammed return to homeostasis. The use of chemical
mediators and their analogs to mimic natural agonists
of resolution has the exciting potential to seed a new
genus of therapeutics for asthma and related inflam-
matory diseases.
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